| Abstrakt: |
A recent report from Tawam Hospital provides new insights into end stage kidney disease (ESKD) in patients with Familial Mediterranean Fever (FMF). FMF is an inherited genetic disorder characterized by recurrent episodes of fever, serositis, arthritis, and skin rash. The study found that long-term colchicine therapy can reduce FMF attacks and the risk of AA amyloidosis, a complication of FMF that can lead to progressive renal failure. The researchers identified only two FMF patients in their dialysis cohort over a 12-year period, highlighting the limited data on ESKD in FMF. Colchicine therapy is crucial in managing FMF attacks and preventing other organ AA amyloidosis in ESKD-FMF patients. [Extracted from the article] |
